中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

260 records (took 0.037 seconds)

    Free radical scavengers or promoters thereof as therapeutic adjuvants in preterm parturition
    131.
    发明授权
    Free radical scavengers or promoters thereof as therapeutic adjuvants in preterm parturition 有权
    自由基清除剂或其启动子作为早产分娩中的治疗佐剂

    公开(公告)号：US06852698B2

    公开(公告)日：2005-02-08

    申请号：US09765476

    申请日：2001-01-18

    Applicant: Irina A. Buhimschi ,  Carl P. Weiner

    Inventor： Irina A. Buhimschi ,  Carl P. Weiner

    IPC: A61K31/015 ,  A61K31/198 ,  A61K31/355 ,  A61K31/375 ,  A61K38/06 ,  A61K38/44 ,  A61K49/06 ,  A61K49/20 ,  A61P15/06

    CPC classification number: A61K49/20 ,  A61K31/015 ,  A61K31/198 ,  A61K31/355 ,  A61K31/375 ,  A61K38/063 ,  A61K38/446 ,  A61K49/06 ,  A61K2300/00

    Abstract: The usage of compounds that improve fetal and neonatal outcome of preterm birth is described. These compounds are scavengers of ROS, their precursors, and agents that induce production of the scavengers. Examples of these compounds are glutathione, NAC, antioxidants, and spin trapping compounds. These compounds improve fetal outcome by inhibiting a fetal inflammatory process that may affect the fetus independently of prematurity. This fetal inflammatory response is characterized by increased cytokine and matrix metalloproteases (MMP) levels both in the mother and fetus and may be modulated by ROS at different levels. Targeting ROS formation with compounds such as specific antioxidants, glutathione or spin trapping compounds, their precursors, and/or agents which induce their production will suppress both the direct effects of ROS and its indirect effects through cytokines and MMPs already circulating in the system. This therapeutical intervention would limit the pathophysiologoical chain of events that ultimately leads to PPROM, preterm birth and/or adverse fetal and neonatal outcome.

    Abstract translation: 描述了改善早产胎儿和新生儿结局的化合物的用法。 这些化合物是ROS的清除剂，它们的前体和诱导清除剂生成的试剂。 这些化合物的实例是谷胱甘肽，NAC，抗氧化剂和自旋捕获化合物。 这些化合物通过抑制可能独立于早产儿影响胎儿的胎儿炎症过程来改善胎儿结果。 胎儿炎症反应的特征在于母体和胎儿中增加的细胞因子和基质金属蛋白酶（MMP）水平，并且可能由不同水平的ROS调节。 用化合物如特异性抗氧化剂，谷胱甘肽或自旋捕获化合物，其前体和/或诱导其产生的试剂靶向ROS形成将通过已经在系统中循环的细胞因子和MMP抑制ROS的直接作用及其间接作用。 这种治疗干预将限制最终导致PPROM，早产和/或不良胎儿和新生儿结局的事件的病理生理链。

    Method for treatment of antigenically modified polypeptides
    135.
    发明授权
    Method for treatment of antigenically modified polypeptides 失效

    公开(公告)号：US6146633A

    公开(公告)日：2000-11-14

    申请号：US466660

    申请日：1995-06-06

    Applicant: Vernon C. Stevens

    Inventor： Vernon C. Stevens

    IPC: A61K39/385 ,  A61K39/395 ,  A61P5/00 ,  A61P15/06 ,  A61P15/18 ,  A61P35/00 ,  A61P37/02 ,  C07K14/59 ,  C07K16/18 ,  C07K16/26

    CPC classification number: C07K14/59

    Abstract: Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protein or fragment alone. The chemical modification may be accomplished by attaching the proteins or fragments to carriers such as, for example, bacterial toxoids. The chemical modification can also be accomplished by polymerization of protein fragments. Proteins which can be modified include Follicle Stimulating Hormone and Human Chorionic Gonadotropin. The modified polypeptide may be administered to animals for the purpose of contraception, abortion or treatment of hormone-related disease states and disease disorders, treatment of hormone-associated carcinomas, and to boost the animals' resistance to exogenous proteins, for example viral proteins.

    Antagonists of chaperonin 10
    136.
    发明授权
    Antagonists of chaperonin 10 失效
    伴侣的拮抗剂10

    公开(公告)号：US6113899A

    公开(公告)日：2000-09-05

    申请号：US654618

    申请日：1996-05-29

    Applicant: Halle Morton ,  Alice Christina Cavanagh

    Inventor： Halle Morton ,  Alice Christina Cavanagh

    IPC: G01N33/53 ,  A61K38/00 ,  A61K39/395 ,  A61K45/00 ,  A61P5/00 ,  A61P15/06 ,  A61P15/08 ,  A61P17/00 ,  A61P17/02 ,  A61P25/20 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  A61P37/08 ,  C07K7/06 ,  C07K14/00 ,  C07K14/47 ,  C07K16/18 ,  C12N15/09 ,  C12P21/02 ,  C12P21/08 ,  C12R1/19 ,  C07K16/00 ,  A61K35/14

    CPC classification number: C07K14/4715 ,  C07K16/18 ,  A61K38/00

    Abstract: An antagonist to, or an antibody (Ab) raised against, cpn10 or a recombinant cpn10 with the sequence: GSAGQAFRKFLPLFDRVLVERSAAETVTKGGIMLPEKSQGKVLQATVEAVGSGSKGKGGEIQPVSVKEGDK VLLPEYGGTKVVLDDKDYFLFRDGDILGKYVD is claimed. Also, claimed are: (1) an antagonist or Ab raised against a peptide derived from cpn10, or a peptide with the sequence: Ac-AGQAFRKLPL(C) AGQAFRKFLPLA2 A1AGQAFRKFLPL Ac-A1AGQAFRKFLPL (A1)EKSQGKVLQATA2 A1EKSQGKVLQAT where A1 and A2 are amino acid sequences that may be added to one or both ends of the peptides, and where the peptides may have a single amino acid deletion, addition or substitution; (2) suppressing cellular growth or enhancing immunological activity by admin. of a cpn10 antagonist or anti-cpn10 Ab to a subject; and (3) an assay for measuring anti-cpn10 Ab in a sample by: (a) reacting purified cpn10 with the sample (b) determining the amt. of Ab in the sample by determining the binding between the Ab and cpn10.USE--The cpn 10 antagonist or Ab can be used to terminate pregnancy, suppressing tumour cell growth or enhancing the immune system.

    Abstract translation: 涉及针对cpn10或具有序列：GSAGQAFRKFLPLFDRVLVERSAAETVTKGGIMLPEKSQGKVLQATVEAVGSGSKGKVLQATVEAVGSGSKGKGGEIQPVSVKEGDK VLLPEYGGTKVVLDDKDYFLFRDGDILGKYVD的重组cpn10的抗体（Ab）的拮抗剂或抗体（Ab）。 另外，要求保护的是：（1）针对源自cpn10的肽的拮抗剂或Ab，或具有以下序列的肽：Ac-AGQAFRKLPL（C）AGQAFRKFLPLA2 A1AGQAFRKFLPL Ac-A1AGQAFRKFLPL（A1）EKSQGKVLQATA2 A1EKSQGKVLQAT其中A1和A2为氨基酸 可以加入到肽的一个或两个末端的序列，以及肽可以具有单个氨基酸缺失，添加或取代的序列; （2）通过管理来抑制细胞生长或增强免疫活性。 的cpn10拮抗剂或抗cpn10 Ab; 和（3）通过以下步骤测量样品中的抗cpn10Ab的测定：（a）使纯化的cpn10与样品反应（b）测定amt。 通过确定Ab和cpn10之间的结合，在样品中。 USE- cpn 10拮抗剂或Ab可用于终止妊娠，抑制肿瘤细胞生长或增强免疫系统。

Patent Agency Ranking